Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.

• Status: Completed
• Trial end date: 2015-12-20
• Target enrollment: 0
• Participant gender: All

Summary

This study seeks to evaluate the effect of topical aqueous suppression on the anatomic and functional response to intravitreal anti-vascular endothelial growth factor (VEGF) injections in non-responders with wet age-related macular degeneration.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wills Eye
• Collaborators: J. Arch McNamara Research Fund; Mid Atlantic Retina
• Treatments: Dorzolamide; Endothelial Growth Factors; Timolol

Criteria

Inclusion Criteria:

1. Patient of Wills Eye Hospital Retina Service and/or Mid Atlantic Retina.

2. Volunteer patients age 18 years and older.

3. Healthy enough to participate in the study.

4. Willing and able to consent to participation in the study.

5. Diagnosis of wet age-related macular degeneration

6. Prior treatment with at least 4 injections of anti-VEGF agents in the past 6 months and persistent intraretinal and/or subretinal fluid on SD-OCT at each visit during this period

7. Injection of the same anti-VEGF agent for at least two visits prior to study enrollment

8. Fixed interval between at least two visits prior to study enrollment

Exclusion Criteria:

1. History of uveitis

2. Any ophthalmic surgery within previous 6 months, including cataract extraction.

3. Any history of vitrectomy

4. History of any glaucoma drop usage or prior glaucoma surgery

5. Systemic diuretic or corticosteroid usage

6. Any contraindication (bradycardia, decompensated heart failure, or reactive

7. airway disease) for topical use of a beta-blocker

8. Any history of sulfonamide allergy

-